Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIDGE-CMVhTNF
- Development stage
- Unknown
- Lead developer
- Mologen
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
MIDGE-CMVhTNF is a nonviral gene therapy vector developed by Mologen AG for the intratumoral expression of human tumor necrosis factor-alpha (hTNF-alpha). The vector utilizes the MIDGE (Minimalistic Immunologically Defined Gene Expression) platform, which consists of a small, double-stranded linear DNA molecule sealed with oligonucleotide loops, lacking the bacterial sequences and antibiotic resistance genes typically found in plasmid vectors. This specific construct incorporates a CMV promoter to drive the expression of hTNF-alpha. In preclinical studies, MIDGE-CMVhTNF has demonstrated significantly higher expression levels and improved safety profiles compared to traditional plasmid vectors, with rapid systemic clearance and localized activity following jet-injection into tumors such as melanoma.
- Other names
- MIDGE-hTNFMIDGE-TNF-alpha
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on MIDGE-CMVhTNF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIDGE-CMVhTNF.